|
Name |
(S)-beta-hydroxypalmitic acid
|
Molecular Formula | C16H32O3 | |
IUPAC Name* |
(3S)-3-hydroxyhexadecanoic acid
|
|
SMILES |
CCCCCCCCCCCCC[C@@H](CC(=O)O)O
|
|
InChI |
InChI=1S/C16H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-15(17)14-16(18)19/h15,17H,2-14H2,1H3,(H,18,19)/t15-/m0/s1
|
|
InChIKey |
CBWALJHXHCJYTE-HNNXBMFYSA-N
|
|
Synonyms |
(S)-beta-hydroxypalmitic acid; 3S-hydroxypalmitic acid; 3S-hydroxyhexadecanoic acid; (S)-3-hydroxypalmitic acid; (3S)-3-hydroxyhexadecanoic acid; (s)-3-hydroxyhexadecanoic acid; SCHEMBL6232663; CHEBI:37250; LMFA01050365; ZINC32838986; 16:0(3-OH); Q27117079
|
|
CAS | 83780-74-9 | |
PubChem CID | 10989404 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 272.42 | ALogp: | 5.8 |
HBD: | 2 | HBA: | 3 |
Rotatable Bonds: | 14 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 57.5 | Aromatic Rings: | 0 |
Heavy Atoms: | 19 | QED Weighted: | 0.437 |
Caco-2 Permeability: | -5.029 | MDCK Permeability: | 0.00003840 |
Pgp-inhibitor: | 0.014 | Pgp-substrate: | 0.173 |
Human Intestinal Absorption (HIA): | 0.01 | 20% Bioavailability (F20%): | 0.996 |
30% Bioavailability (F30%): | 0.983 |
Blood-Brain-Barrier Penetration (BBB): | 0.273 | Plasma Protein Binding (PPB): | 97.15% |
Volume Distribution (VD): | 0.364 | Fu: | 1.65% |
CYP1A2-inhibitor: | 0.082 | CYP1A2-substrate: | 0.185 |
CYP2C19-inhibitor: | 0.079 | CYP2C19-substrate: | 0.273 |
CYP2C9-inhibitor: | 0.252 | CYP2C9-substrate: | 0.984 |
CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.048 |
CYP3A4-inhibitor: | 0.015 | CYP3A4-substrate: | 0.026 |
Clearance (CL): | 5.926 | Half-life (T1/2): | 0.741 |
hERG Blockers: | 0.047 | Human Hepatotoxicity (H-HT): | 0.041 |
Drug-inuced Liver Injury (DILI): | 0.019 | AMES Toxicity: | 0.006 |
Rat Oral Acute Toxicity: | 0.011 | Maximum Recommended Daily Dose: | 0.451 |
Skin Sensitization: | 0.856 | Carcinogencity: | 0.127 |
Eye Corrosion: | 0.984 | Eye Irritation: | 0.987 |
Respiratory Toxicity: | 0.763 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001612 | 0.830 | D07ILQ | 0.548 | ||||
ENC002101 | 0.742 | D0P1RL | 0.531 | ||||
ENC000378 | 0.719 | D0Z5SM | 0.529 | ||||
ENC001217 | 0.716 | D0O1PH | 0.526 | ||||
ENC000466 | 0.712 | D05ATI | 0.493 | ||||
ENC003362 | 0.694 | D00AOJ | 0.446 | ||||
ENC000972 | 0.689 | D0XN8C | 0.418 | ||||
ENC000050 | 0.677 | D00FGR | 0.407 | ||||
ENC001159 | 0.676 | D0I4DQ | 0.386 | ||||
ENC000781 | 0.667 | D0T9TJ | 0.373 |